A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
NCT06436742
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Congenital Myasthenic Syndrome
CMS
Interventions
BIOLOGICAL:
ARGX-119
OTHER:
Placebo
Sponsor
argenx